Search research articles
Contact Us
Filters
Showing results (111-120 of 131) with videos related to
Page
of 14
Sort By:
Cancer Treatment Reviews
|
January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Blood Cancer Journal
|
March 27, 2024
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, et al.
Ebiomedicine
|
January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Aleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Therapeutic Advances in Medical Oncology
|
December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Emma Zattarin, Luigi Mariani, Alice Menichetti, et al.
BMC Medicine
|
November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Maria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
American Journal of Hematology
|
January 18, 2023
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax
Anna Candoni, Davide Lazzarotto, Cristina Papayannidis, et al.
Cell
|
April 2, 2026
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer
Robin Caire, Roberta Bordo, Francesca Zanconato, et al.
American Journal of Hematology
|
January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 131) with videos related to
Sort By:
Page
of 14
Cancer Treatment Reviews
|
January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini, Tomás Pascual, Benedetta Conte, et al.
Blood Cancer Journal
|
March 27, 2024
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Massimiliano Bonifacio, Luigi Scaffidi, Maria Cristina Miggiano, et al.
Ebiomedicine
|
January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Aleix Prat, Valentina Guarneri, Tomás Pascual, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Therapeutic Advances in Medical Oncology
|
December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
Emma Zattarin, Luigi Mariani, Alice Menichetti, et al.
BMC Medicine
|
November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Maria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
American Journal of Hematology
|
January 18, 2023
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax
Anna Candoni, Davide Lazzarotto, Cristina Papayannidis, et al.
Cell
|
April 2, 2026
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer
Robin Caire, Roberta Bordo, Francesca Zanconato, et al.
American Journal of Hematology
|
January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
L Provenzano, M V Dieci, G Curigliano, et al.
Page
of 14